Acta Scientific Biotechnology

Volume 4 Issue 3 June 2024

Research Article

Unveiling the Molecular Landscape of Neurodegenerative Diseases: A Multi-Omics Approach Highlighting Treatment in Alzheimer's Disease

Sabiha Zarin Khanam[1,2], Vishwa Raj Lal[2], Ariba Anwar[1,2], Quba Raza[1,2], Omama Khatoon[1,2], Nesae Akhdash[1,]2, Aqusa Zaman[1,2], Nausheen Hussain[1,2], Harsimran Kaur Hora[1], Priyangulta Beck[1] and Mukesh Nitin[1]*

[1]Department of Tech Biosciences, Digianalix, Ranchi, Jharkhand, India

[2]Department of Biotechnology, Jamshedpur Women's University, Jamshedpur, Jharkhand, India

***Corresponding Author:** Mukesh Nitin, Department of Tech Biosciences, Digianalix, Ranchi, Jharkhand, India.

Received: May 28, 2024

Published: June 20, 2024

Abstract

Neurodegenerative diseases, including Alzheimer's disease (AD), pose a significant burden on healthcare systems globally. Traditional diagnostic and therapeutic strategies often lack the sensitivity and specificity required for early detection and effective intervention. However, recent advancements in multi-omics technologies offer a promising route for revolutionizing the management of these debilitating conditions. This review delves into the current landscape of multi-omics approaches in identifying neurodegenerative diseases, with a particular emphasis on AD. The integration of data from genomics, transcriptomics, proteomics, metabolomics, and epigenomics, highlighting their potential to elucidate the complex interplay of molecular mechanisms underlying neurodegeneration. Furthermore, this study examined the challenges and future prospects of translating multi-omics approaches into clinical practice, paving the way for personalized medicine and improved patient outcomes in neurodegenerative diseases.

Keywords: Neurodegenerative Diseases; Multi-omics; Alzheimer's Disease; Biomarkers; Personalized Medicine

Introduction

Alzheimer disease named after the German psychiatric Alois Alzheimer is the most common type of dementia and can be defined as a slowly progressive neuro degenerative disease characterised by neurotic plaques and neurofibrillary tangle as a result of amyloid beta peptide accumulation is the most affected area of the brain the medial temporal lobe and neocortical structures. Alois Alzheimer noticed presence of amyloid plaques and massive loss of neurones while examining the brain of his first patient that suffered from memory loss and change of personality before dying and describe the condition as serious disease of cerebral cortex and named this medical condition as Alzheimer's disease. Neurodegenerative diseases, characterized by progressive degeneration of neurons, represent a significant burden on global healthcare systems. Among these disorders, Alzheimer's disease (AD) stands out as the most common cause of dementia, affecting millions of individuals worldwide. Despite decades of research, effective treatments for AD remain elusive, underscoring the urgent need for innovative diagnostic and therapeutic strategies. Multi-omics approaches, which integrate data from various molecular levels, offer a comprehensive understanding of the intricate pathophysiology of neurodegenerative diseases, including AD [1]. With applying various techniques towards this multi based methods involving genomics, metabolomics and computational biology we can harness various unanswered questions targeting pathways and gene regulation during AD [2]. Bioinformatics and next-generation sequencing has resulted in the identification of numerous genes providing direct role in metabolic pathways to neurodegenerative diseases [3]. The established cure for AD still remain challenge, however, the effects and progressions of the disease is reported to be controlled to a limited extent [1]. In this review multi approach

and strategies are highlighted that are recently in high demand and adapted widely that can open new clues and designing strategies for future researchers to find cost effective and widely accepted solution to cure AD in upcoming future.

Genomics: unveiling the genetic landscape of Alzheimer's disease

The intricate web of genetic factors plays a crucial role in the development and progression of Alzheimer's disease (AD). Deciphering this genetic landscape has been a cornerstone of research efforts, paving the way for a deeper understanding of the disease and the identification of potential therapeutic targets. This section delves into the key findings from genomic studies in AD research.

Genetic risk factors: unmasking susceptibility genes

Genome-wide association studies (GWAS) [4] and whole-genome sequencing have been instrumental in pinpointing specific genetic variants associated with an increased risk of developing AD. Among these, the apolipoprotein E (APOE) gene stands out as the most well-known risk factor, particularly the APOE ε4 allele. Individuals carrying one or two copies of this allele exhibit a significantly higher susceptibility to AD compared to those with the APOE ε3 allele.

Early-Onset Alzheimer's: Mutations with devastating consequences

While AD typically manifests later in life, a subset of individuals experience early-onset forms with symptoms appearing as early as the 30s or 40s. This often stems from mutations in specific genes, including amyloid precursor protein (APP), presenilin 1 (PSEN1), and presenilin 2 (PSEN2) [5]. These mutations have a dominant effect, meaning that inheriting even a single copy significantly increases the risk of developing early-onset familial AD.

Late-Onset Alzheimer's: A complex polygenic landscape

Beyond the APOE gene, GWAS have identified numerous other genes associated with late-onset AD, which represents the most common form of the disease. These include genes involved in diverse biological processes such as immune response (CLU), lipid metabolism (CR1), synaptic function (PICALM), and intracellular signaling (BIN1) [6]. This highlights the intricate interplay of multiple genetic factors in late-onset AD, suggesting a complex polygenic inheritance pattern.

Beyond Genetics: Environmental and lifestyle influences

It is crucial to recognize that the development of AD is not solely dictated by genetics. Environmental factors like exposure to toxins, head injuries, and certain lifestyle choices, such as smoking and physical inactivity, can also contribute to the risk of developing the disease. Furthermore, the interplay between genetic and environmental factors likely plays a significant role in individual susceptibility.

Genomic research and therapeutic implications

The insights gleaned from genomic studies have significantly advanced our understanding of the molecular mechanisms underlying AD. This knowledge has opened doors for the identification of potential therapeutic targets, paving the way for the development of novel treatments aimed at preventing or slowing disease progression. Targeting the production and aggregation of amyloid-β and tau proteins, the hallmarks of AD pathology, remains a major focus of ongoing drug development efforts [7].

Transcriptomics: Unveiling gene expression patterns in AD

Transcriptomic profiling enables the comprehensive analysis of gene expression patterns in neurodegenerative diseases. RNA sequencing (RNA-seq) studies have revealed dysregulated transcriptomic signatures associated with AD progression, including alterations in synaptic function, immune response, and mitochondrial dysfunction. Moreover, the integration of transcriptomic data with other omics modalities has elucidated novel molecular pathways implicated in AD pathophysiology. Alzheimer's disease (AD) is a slowly-progressing neurodegenerative disorder, starting with mild memory loss and culminating in severe impairment of broad executive and cognitive functions [8,9]. AD pathophysiology involves neuron-glia interactions, supported by transcriptomic and epigenomic analyses that reveal downregulation of neuronal functions and upregulation of innate immune responses in AD brains [10,11]. Transcriptomic approaches in ıdentifying the functıonal aspects of gene regulations aid in opening new insights to AD diagnostics and treatment in pathophysiology as shown in Figure 1.

Table 1: List of Genes associated with AD.

Gene	Function	Association with AD
APOE	Apolipoprotein E	Strongest genetic risk factor for late-onset AD; APOE ε4 allele significantly increases risk
APP	Amyloid precursor protein	Mutations in this gene lead to early-onset familial AD; plays a role in Aβ production
PSEN1 and PSEN2	Presenilin 1 and 2	Mutations in these genes also cause early-onset familial AD; involved in Aβ processing
CLU	Clusterin	Associated with late-onset AD; involved in protein chaperoning and clearance
CR1	Complement component receptor 1	Linked to late-onset AD; involved in the immune response
PICALM	Phosphatidylinositol-binding clathrin assembly protein	Genome-wide association studies link it to late-onset AD; implicated in endocytosis and Aβ clearance
BIN1	Bridging integrator 1	Associated with late-onset AD; involved in intracellular signaling and protein trafficking
TREM2	Triggering receptor expressed on myeloid cells 2	Variants associated with increased risk of AD; plays a role in microglial function and immune response
ABCA7	ATP-binding cassette subfamily A member 7	Associated with late-onset AD; involved in cholesterol transport and Aβ clearance
SORL1	Sortilin-related receptor 1	Protective gene; variants associated with decreased risk of AD; involved in Aβ trafficking and clearance



Figure 1: Structured pipeline highlighting steps involved in utilizing transcriptomics to investigate AD.

However, bulk-tissue level resolution likely masks the complexity of alterations across cells and within cell groups, especially for lowly-represented cell types [10]. Potential changes in cell composition during neurodegeneration also confound the distinction between composition and activity changes in a given cell type. Finally, the complex interplay between protective and damaging molecular processes, within and across cell types, further contributes to the difficulty in interpreting tissue-resolution disease signatures.

Single-cell RNA sequencing (scRNA-seq) provides an alternative approach to study the cellular heterogeneity of the brain by profiling tens of thousands of individual cells [12,13]. With the goal of characterizing the complex cellular changes in AD brain pathology, here we provide the first single-cell view of AD pathology, profiling 80,660 droplet-based single-nucleus cortical transcriptomes across 48 individuals with varying degrees of AD pathology, and across both sexes [12,14]. The resulting resource paints a unique cellular-level view of transcriptional alterations associated with AD pathology, and reveals cell type-specific and shared gene expression perturbations, disease-associated cellular subpopulations, and sex-biased transcriptional responses [15].

Proteomics: Protein dynamics in AD

Proteomics, the comprehensive analysis of protein expression and function, offers a powerful lens to investigate the dynamic changes occurring within the protein landscape of neurodegenerative diseases like Alzheimer's disease (AD). Mass spectrometry-based proteomic techniques enable the identification and quantification of protein alterations associated with AD pathology, including key players like amyloid-β (Aβ) peptides and tau proteins [16,17]. Furthermore, proteogenomic analyses, which combine proteomics with genomics, have shed light on crucial post-translational modifications and protein-protein interactions relevant to AD pathogenesis.

Unveiling biomarkers for diagnosis and monitoring

Proteomics plays a vital role in the discovery of biomarkers for AD. By analyzing protein profiles in brain tissue, cerebrospinal fluid (CSF), and even blood samples from AD patients compared to healthy individuals, researchers can identify proteins that exhibit changes in expression, modification, or aggregation. These proteins hold immense promise as biomarkers for diagnosing AD, predicting disease progression, and monitoring the effectiveness of therapeutic interventions. A prime example is the established use of Aβ and tau protein levels in CSF as diagnostic biomarkers for AD [17].

Deciphering protein pathways in AD

Proteomics facilitates the comprehensive profiling of protein expression levels and post-translational modifications (PTMs) within the context of AD. By mapping protein pathways and networks, researchers can pinpoint key molecular players involved in disease progression. This includes proteins implicated in various pathological processes such as Aβ aggregation, tau hyperphosphorylation, neuroinflammation, impaired synaptic function, and ultimately, neuronal cell death [18].

Unraveling the molecular mechanisms of AD

Proteomic studies provide invaluable insights into the molecular underpinnings of AD pathology. Analyses have revealed dysregulation of protein degradation pathways like the ubiquitin-proteasome system and autophagy-lysosome pathway, alongside mitochondrial dysfunction, oxidative stress, and alterations in synaptic protein profiles in AD brains. Understanding these molecular pathways is critical for the development of targeted therapeutic strategies aimed at correcting these dysfunctions [19].

Discovering novel drug targets

Proteomics offers a powerful tool for identifying novel drug targets for AD. By pinpointing proteins that are dysregulated or aberrantly modified in AD and play key roles in disease-relevant pathways, researchers can prioritize these proteins as potential targets for drug development. Additionally, proteomic approaches enable the screening of candidate drugs to assess their impact on protein expression, modification, and interaction profiles, aiding in the selection of the most promising candidates for further development.

Personalized medicine for AD

Proteomics holds significant potential for advancing personalized medicine approaches in AD. By analyzing individual variations in protein expression patterns and PTMs, researchers aim to iden-

tify unique biomarker signatures that can predict disease progression. These signatures could then be used to stratify patients into subgroups based on their molecular profiles, paving the way for personalized treatment strategies tailored to individual needs [19].

Table 2: Applications of Proteomics in Alzheimer's Disease Research.

Application	Description	Example
Biomarker Discovery	Identify proteins with altered expression, modification, or aggregation in AD compared to healthy controls.	Identifying Aβ and tau protein levels in CSF as diagnostic biomarkers for AD.
Protein Pathway Analysis	Characterize protein expression patterns and post-translational modifications (PTMs) to understand protein pathways involved in AD progression.	Studying proteins associated with Aβ aggregation, tau hyperphosphorylation, neuroinflammation, and synaptic dysfunction.
Unraveling Disease Mechanisms	Gain insights into the molecular underpinnings of AD by identifying dysregulated protein degradation pathways, mitochondrial dysfunction, oxidative stress, and alterations in synaptic proteins.	Analyzing dysregulation of the ubiquitin-proteasome system and autophagy-lysosome pathway in AD brains.
Drug Target Discovery	Identify proteins that are dysregulated or aberrantly modified in AD and play key roles in disease-relevant pathways as potential targets for drug development.	Prioritizing proteins involved in Aβ aggregation or tau hyperphosphorylation for drug development.
Personalized Medicine	Analyze individual variations in protein expression patterns and PTMs to identify unique biomarker signatures for predicting disease progression and guiding personalized treatment strategies.	Stratifying patients into subgroups based on their molecular profiles for personalized treatment approaches.

Metabolomics

Metabolomics, the study of small molecules known as metabolites, offers valuable insights into the biochemical pathways and metabolic changes associated with Alzheimer's disease (AD). Metabolomics enables the comprehensive profiling of metabolites in biological samples such as blood, [20] and brain tissue. By comparing the metabolite profiles of AD patients with healthy individuals, researchers can identify specific metabolic signatures associated with the disease. These signatures may include alterations in amino acids, lipids, carbohydrates, neurotransmitters, and other metabolites.

Metabolomics holds promise for the discovery of novel biomarkers for Alzheimer's disease. Metabolic changes occurring in the early stages of AD, before the onset of clinical symptoms, may provide diagnostic markers for early detection and intervention. For example, alterations in amyloid and tau metabolism, lipid metabolism, oxidative stress markers, and energy metabolism have been identified as potential biomarkers for AD using metabolomics approaches [20].

Insights into disease pathophysiology

Metabolomics studies provide insights into the underlying metabolic pathways involved in Alzheimer's disease pathophysiology. Dysregulation of various metabolic pathways, including glucose metabolism, lipid metabolism, amino acid metabolism, and neurotransmitter metabolism, has been observed in AD. These metabolic alterations may contribute to neurodegeneration, synaptic dysfunction, and cognitive decline in AD patients.

Metabolomics approaches help to elucidate the molecular mechanisms underlying disease progression and identify metabolic changes associated with different stages of Alzheimer's disease. Furthermore, metabolomic profiling may reveal metabolic differences between AD subtypes, such as early-onset versus late-onset AD, familial versus sporadic AD, or different pathological subtypes (e.g., amyloid-positive versus tau-positive AD).

Drug discovery and therapeutic targets

Metabolomics facilitates the identification of potential drug targets and therapeutic interventions for Alzheimer's disease. By targeting metabolic pathways that are dysregulated in AD, researchers can develop novel pharmacological approaches to modulate disease progression. Metabolomics can also be used to evaluate the efficacy of therapeutic interventions and monitor metabolic responses to treatment in preclinical and clinical studies.

Metabolomics provides a powerful tool for unraveling the metabolic alterations associated with Alzheimer's disease and holds

promise for the discovery of diagnostic biomarkers, elucidation of disease mechanisms, and development of targeted therapeutic strategies aimed at slowing or halting disease progression. Integrating metabolomic data with other omics technologies, such as genomics, proteomics, and transcriptomics, can provide a comprehensive understanding of AD pathophysiology and facilitate personalized medicine approaches for the treatment of this devastating neurodegenerative disorders.

Metabolomic profiling provides a snapshot of the metabolic perturbations occurring in neurodegenerative diseases. By analysing small-molecule metabolites in biological samples, metabolomics studies have identified metabolic dysregulation in AD, including alterations in lipid metabolism, energy metabolism, and neurotransmitter pathways [11]. Integration of metabolomic data with other omics datasets offers a comprehensive view of metabolic reprogramming in AD pathophysiology. The metabolomics studies add new angle of insights to find regulatory roles in metabolites resulting in the discovery of novel biomarkers and development of theraputic targets as shown in Figure 2.



Figure 2: Steps involved in utilizing metabolomics to investigate AD.

Epigenetics: Unveiling the role of epigenetic modifications in Alzheimer's disease

Epigenomics refers to the study of epigenetic modifications, which are heritable changes in gene expression that occur without alterations to the underlying DNA sequence. Epigenetic mechanisms, including DNA methylation, histone modifications, and non-coding RNA regulation, play critical roles in various biological processes, including development, cell differentiation, and disease. In the context of Alzheimer's disease (AD), epigenomics research has shed light on how epigenetic changes contribute to disease pathogenesis using following approaches.

DNA Methylation: A signature of altered gene expression

DNA methylation, the addition of methyl groups to cytosine bases, is one of the most widely studied epigenetic modifications. Altered DNA methylation patterns have been observed in the brains of individuals with Alzheimer's disease. Genome-wide DNA methylation studies have identified differential methylation patterns associated with AD-related genes, including those involved in amyloid-beta metabolism, tau phosphorylation, neuroinflammation, and synaptic function. These epigenetic changes may influence gene expression and contribute to disease progression [12].

Histone Modifications: Orchestrating chromatin structure and gene expression

Histone proteins undergo various post-translational modifications, such as acetylation, methylation, phosphorylation, and ubiquitination, which regulate chromatin structure and gene expression. Dysregulation of histone modifications has been

implicated in Alzheimer's disease. For example, alterations in histone acetylation patterns have been linked to aberrant gene expression profiles in AD brains. Histone deacetylase (HDAC) inhibitors, which modulate histone acetylation, have shown therapeutic potential in preclinical studies of AD.

Non-coding RNAs: Beyond the DNA sequence

Non-coding RNAs, including microRNAs (miRNAs) and long non-coding RNAs (lncRNAs), regulate gene expression post-transcriptionally and epigenetically. Dysregulation of miRNAs and lncRNAs has been reported in Alzheimer's disease and may contribute to disease pathogenesis by modulating the expression of genes involved in neuronal function, synaptic plasticity, and neuroinflammation. Additionally, circulating miRNAs in the blood and cerebrospinal fluid have emerged as potential biomarkers for AD diagnosis and prognosis [21].

Environmental influence on epigenetic regulation

Environmental factors, such as diet, exercise, stress, and exposure to toxins, can influence epigenetic regulation and may contribute to the risk of developing Alzheimer's disease. For example, dietary factors like folate, vitamin B12, and omega-3 fatty acids are involved in one-carbon metabolism, which contributes to DNA methylation. Lifestyle interventions targeting epigenetic mechanisms may have the potential to mitigate the risk of AD or delay disease progression.

Epigenetic Therapeutics: A promising frontier

Understanding the epigenetic mechanisms underlying Alzheimer's disease has led to the exploration of epigenetic therapeutics as potential treatment strategies. Small molecule inhibitors targeting DNA methylation, histone modifications, and non-coding RNAs are being investigated for their ability to modulate gene expression and potentially modify disease progression in AD.

Epigenomics research has provided valuable insights into the role of epigenetic modifications in Alzheimer's disease, highlighting the intricate interplay between genetic and environmental factors in disease pathogenesis. Further studies are needed to elucidate the causal relationships between epigenetic changes and AD pathology and to develop effective epigenetic-based therapies for the prevention and treatment of Alzheimer's disease [14].

Epigenetic modifications play a crucial role in regulating gene expression patterns in neurodegenerative diseases. Epigenomic studies have elucidated aberrant DNA methylation, histone modifications, and non-coding RNA dysregulation associated with AD pathology. Moreover, epigenome-wide association studies (EWAS) have identified epigenetic signatures predictive of AD risk and progression, highlighting the potential for epigenetic biomarkers in AD diagnosis and prognosis as represented in Figure 3.



Figure 3: Epigenetic Modifications in Alzheimer's Disease.

Challenges and future directions in multi-omics research for Alzheimer's disease

Despite the immense potential of multi-omics approaches in unraveling the molecular underpinnings of Alzheimer's disease (AD), significant challenges remain. These challenges need to be addressed to fully realize the potential of this approach for improving AD diagnosis, treatment, and ultimately, patient outcomes. One of the major challenges lies in integrating and harmonizing data generated from various omics platforms. Each platform has its unique strengths, limitations, and data formats. Effective strategies are needed to combine data from genomics, transcriptomics, proteomics, metabolomics, and epigenomics to generate a comprehensive picture of the complex biological processes underlying AD. This requires the development of standardized protocols for sample collection, data processing, and analysis pipelines to ensure data compatibility and facilitate meaningful comparisons across different omics datasets [22].

Another challenge is the inherent heterogeneity of biological samples, both within and between individuals with AD. Factors like age, ethnicity, lifestyle choices, and disease progression can contribute to substantial variability in omics data. Robust statistical methods and computational tools are necessary to account for this heterogeneity and identify robust and generalizable findings from multi-omics studies [22]. The analysis of large-scale omics datasets also requires sophisticated computational tools and infrastructure. Developing efficient algorithms for data processing, dimensionality reduction, network analysis, and integration across different omics layers is crucial for extracting meaningful biological insights from multi-omics data [22].

Translating multi-omics findings into clinically relevant applications presents another hurdle. Omics-based biomarkers need to be validated in large and diverse patient cohorts to ensure their diagnostic accuracy and generalizability. Furthermore, developing standardized protocols for omics-based diagnostics and therapeutics requires close collaboration between researchers, clinicians, and regulatory agencies [22].

Current and future landscape of Alzheimer's disease diagnosis and treatment

Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterized by cognitive decline and memory loss. There is currently no single definitive test for diagnosing AD. However, several methods are employed to reach an accurate diagnosis, often relying on a combination of approaches.

Current diagnostic strategies

- **Clinical Evaluation:** A comprehensive medical history and neurological examination are performed to assess cognitive function, memory, and other neurological impairments. Neuropsychological Testing: Standardized cognitive tests are used to evaluate memory, thinking skills, language, and problem-solving abilities.

- **Imaging Techniques:** Brain imaging techniques, such as Magnetic Resonance Imaging (MRI) and Computed Tomography (CT), can help rule out other potential causes of dementia and visualize structural changes in the brain associated with AD. Biomarkers: Cerebrospinal fluid (CSF) analysis or Positron Emission Tomography (PET) scans can detect the presence of amyloid-beta plaques and tau tangles, which are hallmarks of AD pathology. However, these techniques are not routinely used in all patients due to cost and invasiveness considerations [13,22].

Current treatment strategies

- **Medications:** Cholinesterase inhibitors and memantine are medications approved by the US Food and Drug Administration (FDA) for treating symptoms of AD, such as memory loss and cognitive decline. However, their long-term benefits are modest.

- **Non-pharmacological Interventions:** Cognitive stimulation therapies, behavioral interventions, and lifestyle modifications, such as exercises.

Advanced tools and technologies for future AD diagnosis and treatment

The future of AD diagnosis and treatment holds promise for earlier detection, more targeted therapies, and potentially disease-modifying interventions. Here's an exploration of some promising advancements:

- **Biomarkers for Early Detection:** Advancements in imaging techniques like PET scans using tau tracers are improving

the ability to detect tau pathology, a crucial step in earlier and more accurate AD diagnosis. Additionally, blood tests for biomarkers like neurofilament light (NfL) are being explored for their potential in non-invasive and convenient early detection [13].

- **Genomics and Proteomics:** High-throughput analyses of genetic and protein profiles can identify individuals with an increased risk of developing AD, allowing for preventative measures and early intervention strategies. Moreover, these approaches can aid in the discovery of novel drug targets for personalized treatment approaches [22].

- **Digital Health Technologies:** Wearable devices that track sleep patterns, activity levels, and cognitive performance can provide valuable data for monitoring disease progression and the effectiveness of treatment strategies. Smartphone apps with cognitive exercises and games may offer opportunities for cognitive stimulation and potentially slowing cognitive decline [23].

- **Artificial Intelligence (AI) and Machine Learning:** AI algorithms can analyze vast datasets encompassing genetic, imaging, and clinical data to identify patterns associated with AD progression risk and predict individual responses to specific treatments. This paves the way for AI-driven personalized medicine approaches in AD [22].

- **Neurostimulation Therapies**: Techniques like transcranial magnetic stimulation (TMS) and transcranial direct current stimulation (tDCS) are being explored as potential treatments to improve cognitive function and communication in AD patients. While still in the early stages of research, these non-invasive brain stimulation methods hold promise for future therapeutic interventions [22].

Unveiling the role of rare variants in Alzheimer's Disease: Insights from whole-genome sequencing

Alzheimer's disease (AD) is a complex neurodegenerative disorder characterized by progressive cognitive decline and memory loss. While genome-wide association studies (GWAS) have identified numerous common genetic variants associated with AD risk, these variants typically have small effects. Whole-genome sequencing (WGS) offers a powerful tool to explore the contribution of rare genetic variants to AD susceptibility.

This section delves into a recent study by Prokopenko et al. (2023) that employed WGS to investigate the association between rare variants and AD status in a large family-based dataset and an independent case-control cohort [24].

Discovery and prioritization of rare variants

The researchers utilized the FBAT Toolkit for family-based association analysis and logistic regression for case-control comparisons. This approach identified a total of 24,301 rare variants ($P < 0.01$) potentially associated with AD. However, an observed deflation of test statistics suggested a conservative bias in the analysis, potentially due to limited family sizes or low variant frequencies.

Despite the initial findings, none of the identified variants reached genome-wide significance ($P < 5\times10–8$). Nevertheless, 271 variants with $P < 5\times10^{-4}$ were prioritized for further evaluation based on their potential relevance to AD pathogenesis.

Replication and validation

The prioritized variants were assessed in an independent WGS case-control dataset. This validation step identified two promising variants as rs74065194, located approximately 200kb downstream from the SEL1L gene (MAF = 0.0066; Pmeta = 0.011) and rs192471919, located in an intronic region of the FNBP1L gene (MAF = 0.0054; Pmeta = 0.017). These variants exhibited nominal replication with the same direction of effect observed in the discovery datasets. Interestingly, rs192471919 displayed a nominally significant association (P = 0.008) with the same effect direction in an independent study by Jansen et al. (2019). The research identified 13 rare-variant signals (four from single-variant and nine from spatial-clustering analyses) associated with AD across both discovery and replication cohorts. These variants appear to be functionally linked to synaptic function and neuronal development, potentially implicating distinct pathways compared to those associated with common variants (microglial/innate immunity) [24]. Thus use of WGS greatly add new values to variant detection and also open new approaches ın AD treatment.

Conclusion

In conclusion, Alzheimer's disease presents a complex challenge, but recent advancements in multi-omics technologies and our understanding of the disease's molecular underpinnings offer a glimmer of hope. By integrating data from genomics, transcrip-

tomics, proteomics, and other omics platforms, researchers are gaining deeper insights into disease mechanisms, identifying novel therapeutic targets, and paving the way for personalized medicine approaches. While challenges are still present in data analysis and overcoming heterogeneity, continued research and collaboration across disciplines hold the key to unlocking the full potential of multi-omics for revolutionizing AD diagnosis, treatment, and ultimately, a cure.

Acknowledgements

We would like to thank Digianalix research facility for providing resources.

Conflict of Interest

There is no conflict of interest.

Bibliography

1. Strassnig M and Ganguli M. "About a peculiar disease of the cerebral cortex: Alzheimer's original case revisited". *Psychiatry (Edgmont)* 2.9 (2005): 30.
2. Mishra S., *et al*. "Genomics and Drug Discovery Strategies: The Role of Natural Compounds and Its Receptor in Alzheimer's Disease". *Cureus* 16.1 (2024).
3. Bertram L. "Next generation sequencing in Alzheimer's disease". *Systems Biology of Alzheimer's Disease* (2016): 281-297.
4. Gagliano S. A., *et al*. "Genomics implicates adaptive and innate immunity in Alzheimer's and Parkinson's diseases". *Annals of Clinical and Translational Neurology* 3.12 (2016): 924-933.
5. Cruchaga C., *et al*. "Polygenic risk score of sporadic late-onset Alzheimer's disease reveals a shared architecture with the familial and early-onset forms". *Alzheimer's and Dementia* 14.2 (2018): 205-214.
6. Ridge P. G., *et al*. "Assessment of the genetic variance of late-onset Alzheimer's disease". *Neurobiology of Aging* 41 (2016): 200-e13.
7. Giri M., *et al.* "Genes associated with Alzheimer's disease: an overview and current status". *Clinical Interventions in Aging* (2016): 665-681.
8. Johnson EC B., *et al*. "Deep proteomic network analysis of Alzheimer's disease brain reveals alterations in RNA binding proteins and RNA splicing associated with disease". *Molecular Neurodegeneration* 13 (2018): 1-22.
9. Gagliano S A., *et al*. "Genomics implicates adaptive and innate immunity in Alzheimer's and Parkinson's diseases". *Annals of Clinical and Translational Neurology* 3.12 (2016): 924-933.
10. Cruchaga C., *et al*. "Polygenic risk score of sporadic late-onset Alzheimer's disease reveals a shared architecture with the familial and early-onset forms". *Alzheimer's and Dementia* 14.2 (2018): 205-214.
11. Wilkins J M and Trushina E. "Application of metabolomics in Alzheimer's disease". *Frontiers in Neurology* 8 (2018): 323079.
12. Hwang J-Y., *et al*. "The emerging field of epigenetics in neurodegeneration and neuroprotection". *Nature Reviews Neuroscience* 18.6 (2017): 347-361.
13. Ames KC., *et al.* "Neural dynamics of reaching following incorrect or absent motor preparation". *Neuron* 81.2 (2014): 438-451.
14. X., *et al*. "The expression of microRNA miR-107 decreases early in Alzheimer's disease and may accelerate disease progression through regulation of β-site amyloid precursor protein-cleaving enzyme 1". *Journal of Neuroscience* 28.5 (2008): 1213-1223.
15. Mathys H., *et al*. "Single-cell transcriptomic analysis of Alzheimer's disease". *Nature* 570.7761 (2019): 332-337.
16. Hardy J and Dennis JS. "The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics". *Science* 297.5580 (2002): 353-356.
17. Zhang J., *et al*. "CSF multianalyte profile distinguishes Alzheimer and Parkinson diseases". *American Journal of Clinical Pathology* 129.4 (2008): 526-529.
18. Selkoe DJ. "Alzheimer's disease: genes, proteins, and therapy". *Physiological Reviews* 2 (2001): 741-766.
19. Kumar D., *et al.* "A comprehensive review of Alzheimer's association with related proteins: Pathological role and therapeutic significance". *Current Neuropharmacology* 18.8 (2020): 674-695.

20. McGrowder D A., *et al.* "Cerebrospinal fluid biomarkers of Alzheimer's disease: current evidence and future perspectives". *Brain Sciences* 11.2 (2021): 215.

21. Satoh J-I. "Molecular network of microRNA targets in Alzheimer's disease brains". *Experimental Neurology* 235.2 (2012): 436-446.

22. Cummings J., *et al.* "Alzheimer's disease drug development pipeline: 2019". *Alzheimer's and Dementia: Translational Research and Clinical Interventions* 5 (2019): 272-293.

23. Al-Faraj A., *et al.* "Telemedicine in Neurology: Challenges and Opportunities". *Research Square* (2023).

24. Prokopenko D., *et al.* "Whole-genome sequencing reveals new Alzheimer's disease–associated rare variants in loci related to synaptic function and neuronal development". *Alzheimer's and Dementia* 17.9 (2021): 1509-1527.